Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03693430 · ClinicalTrials.gov registry record · Phase 3
Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 304
- Enrollment target
NCT03693430 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 304 participants.
The verdict
NCT03693430, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 304 participants
- Enrollment target
Study Summary
This study will look at the change in body weight from the start to the end of the study. Researchers will compare the weight loss in people taking semaglutide (a new medicine) to people taking "dummy" medicine. In addition to taking the medicine, participants will also have talks with study staff about healthy food choices, how the participant can be more physically active and what participants can do to lose weight. Participants will either get semaglutide or "dummy" medicine - which treatment the participant gets is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The study will last for about 2 years. The participants will have 19 clinic visits and 15 phone calls with the study doctor.
Interventions
- DRUG Semaglutide
- DRUG Placebo (Semaglutide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2018-10-05 |
| Est. Completion | 2021-03-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03693430
The ClinicalTrials.gov registry entry for NCT03693430 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 304 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Semaglutide is the first listed.
NCT03693430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03693430 about?
NCT03693430 is a clinical study titled "Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity". This study will look at the change in body weight from the start to the end of the study. Researchers will compare the weight loss in people taking semaglutide (a new medicine) to people taking "dummy" medicine. In addition to taking the medicine, participants will also have talks with study staff a...
What is the current status of trial NCT03693430?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 304 participants. The study started on 2018-10-05. Estimated completion is 2021-03-23.
What interventions are being tested in trial NCT03693430?
The interventions under investigation include: Semaglutide (DRUG), Placebo (Semaglutide) (DRUG).
Who is sponsoring clinical trial NCT03693430?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.